**Strong equity market conditions and a robust pipeline of issuers continue to support IPO activity through the final months of 2026.** With dozens of deals already priced year-to-date—including recent listings like ADARx Pharmaceuticals and upcoming ones such as Oura—trader consensus reflects high implied probabilities for additional offerings before year-end. Recent Fed rate hikes to the 3.75–4.00% target range, 10-year Treasury yields near 5%, and concerns over AI spending have introduced selectivity and tempered aftermarket performance in Q3, yet larger, later-stage companies in AI infrastructure, biotech, and consumer sectors maintain access. Key near-term catalysts include October filings from names like Anthropic and ongoing equity market stability, which could either accelerate or delay marginal deals into 2027 depending on volatility and macroeconomic data releases.